Skip to main content

JHOP - June 2024 Vol 14, No 3

Case Reports
Original Research
Practical Issues in Pharmacy Management
Case Reports
Case Reports, Leukemia, Dose Escalation/Reduction, Adverse Events, Tyrosine Kinase Inhibitor, Targeted Therapies
Split- and Reduced-Dose Imatinib in Chronic Myeloid Leukemia: Case Report
Justin Liauw, PharmD; Robert Brunault, PharmD; Matt Quesenberry, MD; Brianna Bakow, MD
Read More
Original Research
Online First
Original Research, Adverse Events, Infusion Issues, Chemotherapy, Monoclonal Antibodies
Evaluation of Acute Irinotecan-Related AEs at 2 Different Infusion Rates in Patients With Gastrointestinal Malignancies
Nhi Y. Bui, PharmD; Mona Hammam, PharmD, MS, BCPS, FISMP; Benjamin Schlechter, MD; Gayle Blouin, PharmD, BCOP
Read More
Original Research, Venetoclax, Leukemia, Adverse Events, Chemotherapy
Addition of Venetoclax to Intensive Induction Regimens for AML Does Not Increase Rates of Febrile Neutropenia
Amanda K. DeWitt, PharmD; Carlina J. Grindeland, PharmD, BCPS, BCPPS; Natalie M. Schulze, PharmD, BCOP
Read More
Original Research, Adverse Events, Immunotherapy, Checkpoint Inhibitors, Dose Escalation/Reduction
Comparison of Adverse Events Between 2 Pembrolizumab Monotherapy Dosing Regimens
Kateryna Kovalenko, PharmD, BCOP; John Garrett, PharmD, MS, BCPS, BCOP, APh; Kathryn Bollin, MD; Harminder Sikand, PharmD, FCSHP, FASHP, FCCP; Leah Puglisi, MSc
Read More
Practical Issues in Pharmacy Management
Online First
Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols, Breast Cancer, CDK4/6 Inhibitors, Adverse Events
Evaluation of Pharmacist-Driven Approach to Monitoring for Neutropenia Related to CDK4/6 Inhibitors in Women With Advanced Breast Cancer
Jianne De Raya, PharmD, and Jessie Modlin, PharmD, BCOP
Read More